Amy Sarah Ginsburg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Amy Sarah Ginsburg has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Susanne May
Clinical Trials Center, University of Washington, Seattle, USA
13 shared publications- John Mark Ansermino
University of British Columbia
7 shared publications Keith P Klugman
Bill & Melinda Gates Foundation, Seattle, WA, USA
7 shared publicationsRoseline Ochieng
Department of Paediatrics, Aga Khan University, Nairobi, Kenya
7 shared publications- Jesse Coleman
Evaluation of Technologies for Neonates in Africa (ETNA), Aga Khan University Hospital, Nairobi, Kenya
6 shared publications Jun Hwang
University of Washington, Seattle, USA
6 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in The Lancet Global Health
Childhood pneumonia: a stress test for health systems
- 12 November 2026
- Published by Elsevier in The Lancet Global Health
Open AccessChildhood pneumonia: a stress test for health systems
- Open Access
- 12 November 2025
- Published by Elsevier in The Lancet Global Health
- Vol. 13 (12) , e2002-e2003
Paediatric pneumonia: a call for point-of-care diagnostics and prognostics
- 12 November 2025
- Published by Elsevier in The Lancet Global Health
- Vol. 13 (12) , e2002-e2003
Open AccessPaediatric pneumonia: a call for point-of-care diagnostics and prognostics
- Open Access
An Observational Study of Pulse Oximeter Alarms in a Newborn Unit at a Tertiary Facility in Kenya
Background: Continuous pulse oximetry monitoring of neonates in the intensive care unit improves clinical outcomes. However, monitoring will only be effective if actions are taken based on the results of appropriate monitoring. While threshold alarms are used to alert providers about clinical deterioration, alarm fatigue significantly degrades the effectiveness of alarms if the thresholds are not adapted based on the clinical status of each neonate, including changes seen in neonatal physiology. Methods: As part of a quality improvement project aimed at reducing the risk of apnea of prematurity, which included caffeine citrate administration, we conducted an observational study of alarms during the implementation of continuous pulse oximetry in a newborn unit (NBU) of a tertiary teaching and referral healthcare facility in Kenya. Default alarm thresholds were set at 85 to 96% for oxygen saturation (SpO 2 ) and 90 to 200 beats per minute (bpm) for pulse rate (PR). Results: Among 49 neonates with a median birth weight of 1.3 kilograms (IQR,329 grams) at admission, 16,212 hours of data were recorded. Respiratory support was provided on 28% of patient days. The median number of alarms per hour per neonate was 12 (IQR,40) visual and 9 (IQR,21) audible alarms. Half of the SpO 2 values lay outside the thresholds, with 44% exceeding the upper threshold of 96%, with a median duration of 20 (IQR,72) seconds. The mean for HR was 1 (SD,1.17) alarm per hour per neonate, with 2% of the data lying outside the thresholds. Conclusions: The thresholds for SpO 2 resulted in a high alarm burden. A short alarm delay could have significantly reduced this burden. Setting an upper threshold of 96% in clinically stable babies resulted in a large volume of unnecessary alarms. Adjusting thresholds based on individual neonatal characteristics, including consideration of the need for respiratory support, is recommended. Effective monitoring of neonates requires individualized alarm thresholds and additional smart algorithms specifically designed to detect clinical deterioration.
Open AccessAn Observational Study of Pulse Oximeter Alarms in a Newborn Unit at a Tertiary Facility in Kenya
Background: Continuous pulse oximetry monitoring of neonates in the intensive care unit improves clinical outcomes. However, monitoring will only be effective if actions are taken based on the results of appropriate monitoring. While threshold alarms are used to alert providers about clinical deterioration, alarm fatigue significantly degrades the effectiveness of alarms if the thresholds are not adapted based on the clinical status of each neonate, including changes seen in neonatal physiology. Methods: As part of a quality improvement project aimed at reducing the risk of apnea of prematurity, which included caffeine citrate administration, we conducted an observational study of alarms during the implementation of continuous pulse oximetry in a newborn unit (NBU) of a tertiary teaching and referral healthcare facility in Kenya. Default alarm thresholds were set at 85 to 96% for oxygen saturation (SpO 2 ) and 90 to 200 beats per minute (bpm) for pulse rate (PR). Results: Among 49 neonates with a median birth weight of 1.3 kilograms (IQR,329 grams) at admission, 16,212 hours of data were recorded. Respiratory support was provided on 28% of patient days. The median number of alarms per hour per neonate was 12 (IQR,40) visual and 9 (IQR,21) audible alarms. Half of the SpO 2 values lay outside the thresholds, with 44% exceeding the upper threshold of 96%, with a median duration of 20 (IQR,72) seconds. The mean for HR was 1 (SD,1.17) alarm per hour per neonate, with 2% of the data lying outside the thresholds. Conclusions: The thresholds for SpO 2 resulted in a high alarm burden. A short alarm delay could have significantly reduced this burden. Setting an upper threshold of 96% in clinically stable babies resulted in a large volume of unnecessary alarms. Adjusting thresholds based on individual neonatal characteristics, including consideration of the need for respiratory support, is recommended. Effective monitoring of neonates requires individualized alarm thresholds and additional smart algorithms specifically designed to detect clinical deterioration.
- Open Access
- 31 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
A survey of obstetric ultrasound uses and priorities for artificial intelligence-assisted obstetric ultrasound in low- and middle-income countries
Obstetric ultrasound (OBUS) is recommended as part of antenatal care for pregnant individuals worldwide. To better understand current uses of OBUS in low- and middle-income countries and perceptions regarding potential use of artificial intelligence (AI)-assisted OBUS, we conducted an anonymous online global survey. A total of 176 respondents representing 34 countries participated, including 41% physicians, 49% nurses or midwives, and 6% ultrasound technicians. Most had received OBUS training (72%), reported expertise (60%) and confidence (77%) in OBUS use, and had access to ultrasound (85%). Assessment of gestational age, fetal viability, fetal presentation, and multiple gestation were both the most common OBUS uses and among the most highly prioritized for AI-assisted OBUS development. Most respondents noted ultrasound access was important (84%) and agreed that OBUS improves quality of care (98%) and patient outcomes (97%). Of the 34% expressing reservations associated with using AI-assisted OBUS, healthcare providers not understanding the technology (71%), misdiagnosis (62%), and cost (59%) were the most common. Better understanding the OBUS user, the pregnant individual, and the context, and taking care to ensure responsible, sustainable, and inclusive development and use of AI-assisted OBUS will be critical to successful integration and implementation and to increasing access to OBUS.
- 31 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessA survey of obstetric ultrasound uses and priorities for artificial intelligence-assisted obstetric ultrasound in low- and middle-income countries
Obstetric ultrasound (OBUS) is recommended as part of antenatal care for pregnant individuals worldwide. To better understand current uses of OBUS in low- and middle-income countries and perceptions regarding potential use of artificial intelligence (AI)-assisted OBUS, we conducted an anonymous online global survey. A total of 176 respondents representing 34 countries participated, including 41% physicians, 49% nurses or midwives, and 6% ultrasound technicians. Most had received OBUS training (72%), reported expertise (60%) and confidence (77%) in OBUS use, and had access to ultrasound (85%). Assessment of gestational age, fetal viability, fetal presentation, and multiple gestation were both the most common OBUS uses and among the most highly prioritized for AI-assisted OBUS development. Most respondents noted ultrasound access was important (84%) and agreed that OBUS improves quality of care (98%) and patient outcomes (97%). Of the 34% expressing reservations associated with using AI-assisted OBUS, healthcare providers not understanding the technology (71%), misdiagnosis (62%), and cost (59%) were the most common. Better understanding the OBUS user, the pregnant individual, and the context, and taking care to ensure responsible, sustainable, and inclusive development and use of AI-assisted OBUS will be critical to successful integration and implementation and to increasing access to OBUS.
- Open Access
- 11 November 2024
- Published by Elsevier in The Lancet Global Health
- Vol. 12 (12) , e1928-e1929
Access to antibiotics for pneumonia and sepsis in LMICs
- 11 November 2024
- Published by Elsevier in The Lancet Global Health
- Vol. 12 (12) , e1928-e1929
Open AccessAccess to antibiotics for pneumonia and sepsis in LMICs
- Open Access
- 14 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-6
Weight change in the first 30 days among infants born less than 2000 grams in Guinea-Bissau and Uganda
Despite the high prevalence of low birth weight infants in sub-Saharan Africa and the associated poor outcomes, weight change during the newborn period has not been well characterized for this population. We prospectively assessed growth over the first 30 days among 120 infants born < 2000 g (g) in Guinea‐Bissau and Uganda, and compared it to a similar cohort of 420 infants born ≥ 2000 g. Among those born < 2000 g, mean birth weight was 1747 ± 164 g, and initial weight loss was 8.25 ± 4.40% of birth weight prior to the initiation of weight gain at a median of 3 (interquartile range 2, 4) days of age. This initial weight loss was more pronounced (8.25 vs 6.06%; p < 0.001) and lasted longer (median 3 vs 2 days; p < 0.001) than for infants born ≥ 2000 g. The initial period of weight loss was an important predictor of growth at 30 days in both cohorts. Infants born < 2000 g on average grew proportionately to their size at birth but did not experience catch-up growth; their weights at 30 days remained much lower than that of infants born ≥ 2000 g and most remained severely underweight. Targeted interventions to optimize early growth should be investigated.
- 14 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-6
Open AccessWeight change in the first 30 days among infants born less than 2000 grams in Guinea-Bissau and Uganda
Despite the high prevalence of low birth weight infants in sub-Saharan Africa and the associated poor outcomes, weight change during the newborn period has not been well characterized for this population. We prospectively assessed growth over the first 30 days among 120 infants born < 2000 g (g) in Guinea‐Bissau and Uganda, and compared it to a similar cohort of 420 infants born ≥ 2000 g. Among those born < 2000 g, mean birth weight was 1747 ± 164 g, and initial weight loss was 8.25 ± 4.40% of birth weight prior to the initiation of weight gain at a median of 3 (interquartile range 2, 4) days of age. This initial weight loss was more pronounced (8.25 vs 6.06%; p < 0.001) and lasted longer (median 3 vs 2 days; p < 0.001) than for infants born ≥ 2000 g. The initial period of weight loss was an important predictor of growth at 30 days in both cohorts. Infants born < 2000 g on average grew proportionately to their size at birth but did not experience catch-up growth; their weights at 30 days remained much lower than that of infants born ≥ 2000 g and most remained severely underweight. Targeted interventions to optimize early growth should be investigated.
- Open Access
- 10 November 2023
- Published by Elsevier in The Lancet Global Health
- Vol. 11 (12) , e1849-e1850
Artificial intelligence and pneumonia: a rapidly evolving frontier
- 10 November 2023
- Published by Elsevier in The Lancet Global Health
- Vol. 11 (12) , e1849-e1850
Open AccessArtificial intelligence and pneumonia: a rapidly evolving frontier
- Open Access
- 17 July 2023
- Published by Springer Nature in Implementation Science Communications
- Vol. 4 (1) , 1-12
Developing and testing a clinical care bundle incorporating caffeine citrate to manage apnoea of prematurity in a resource-constrained setting: a mixed methods clinical feasibility study protocol
Background: Apnoea of prematurity (AOP) is a common condition among preterm infants. Methylxanthines, such as caffeine and aminophylline/theophylline, can help prevent and treat AOP. Due to its physiological benefits and fewer side effects, caffeine citrate is recommended for the prevention and treatment of AOP. However, caffeine citrate is not available in most resource-constrained settings (RCS) due to its high cost. Challenges in RCS using caffeine citrate to prevent AOP include identifying eligible preterm infants where gestational age is not always known and the capability for continuous monitoring of vital signs to readily identify apnoea. We aim to develop an evidence-based care bundle that includes caffeine citrate to prevent and manage AOP in tertiary healthcare facilities in Kenya. Methods: This protocol details a prospective mixed-methods clinical feasibility study on using caffeine citrate to manage apnoea of prematurity in a single facility tertiary-care newborn unit (NBU) in Nairobi, Kenya. This study will include a 4-month formative research phase followed by the development of an AOP clinical-care-bundle prototype over 2 months. In the subsequent 4 months, implementation and improvement of the clinical-care-bundle prototype will be undertaken. The baseline data will provide contextualised insights on care practices within the NBU that will inform the development of a context-sensitive AOP clinical-care-bundle prototype. The clinical care bundle will be tested and refined further during an implementation phase of the quality improvement initiative using a PDSA framework underpinned by quantitative and qualitative clinical audits and stakeholders’ engagement. The quantitative component will include all neonates born at gestation age < 34 weeks and any neonate prescribed aminophylline or caffeine citrate admitted to the NBU during the study period. Discussion: There is a need to develop evidence-based and context-sensitive clinical practice guidelines to standardise and improve the management of AOP in RCS. Concerns requiring resolution in implementing such guidelines include diagnosis of apnoea, optimal timing, dosing and administration of caffeine citrate, standardisation of monitoring devices and alarm limits, and discharge protocols. We aim to provide a feasible standardised clinical care bundle for managing AOP in low and middle-income settings.
- 17 July 2023
- Published by Springer Nature in Implementation Science Communications
- Vol. 4 (1) , 1-12
Open AccessDeveloping and testing a clinical care bundle incorporating caffeine citrate to manage apnoea of prematurity in a resource-constrained setting: a mixed methods clinical feasibility study protocol
Background: Apnoea of prematurity (AOP) is a common condition among preterm infants. Methylxanthines, such as caffeine and aminophylline/theophylline, can help prevent and treat AOP. Due to its physiological benefits and fewer side effects, caffeine citrate is recommended for the prevention and treatment of AOP. However, caffeine citrate is not available in most resource-constrained settings (RCS) due to its high cost. Challenges in RCS using caffeine citrate to prevent AOP include identifying eligible preterm infants where gestational age is not always known and the capability for continuous monitoring of vital signs to readily identify apnoea. We aim to develop an evidence-based care bundle that includes caffeine citrate to prevent and manage AOP in tertiary healthcare facilities in Kenya. Methods: This protocol details a prospective mixed-methods clinical feasibility study on using caffeine citrate to manage apnoea of prematurity in a single facility tertiary-care newborn unit (NBU) in Nairobi, Kenya. This study will include a 4-month formative research phase followed by the development of an AOP clinical-care-bundle prototype over 2 months. In the subsequent 4 months, implementation and improvement of the clinical-care-bundle prototype will be undertaken. The baseline data will provide contextualised insights on care practices within the NBU that will inform the development of a context-sensitive AOP clinical-care-bundle prototype. The clinical care bundle will be tested and refined further during an implementation phase of the quality improvement initiative using a PDSA framework underpinned by quantitative and qualitative clinical audits and stakeholders’ engagement. The quantitative component will include all neonates born at gestation age < 34 weeks and any neonate prescribed aminophylline or caffeine citrate admitted to the NBU during the study period. Discussion: There is a need to develop evidence-based and context-sensitive clinical practice guidelines to standardise and improve the management of AOP in RCS. Concerns requiring resolution in implementing such guidelines include diagnosis of apnoea, optimal timing, dosing and administration of caffeine citrate, standardisation of monitoring devices and alarm limits, and discharge protocols. We aim to provide a feasible standardised clinical care bundle for managing AOP in low and middle-income settings.
- Open Access
Measurement Uncertainty in Clinical Validation Studies of Sensors
Accurate clinical sensors and devices are essential to support optimal medical decision-making, and accuracy can be demonstrated through the conduct of clinical validation studies using validated reference sensors and/or devices for comparison. Typically unmeasurable, the true reference value can be substituted with an accepted physiological measurement with an associated uncertainty. We describe a basic model of measurement uncertainty that specifies the factors that may degrade the accuracy of an observed measurement value from a sensor, and we detail validation study design strategies that may be used to quantify and minimize these uncertainties. In addition, we describe a model that extends the observed measurement uncertainty to the resultant clinical decision and the factors that may impact the uncertainty of this decision. Clinical validation studies should be designed to estimate and minimize uncertainty that is unrelated to the sensor accuracy. The contribution of measurement observation uncertainty to clinical decision-making should be minimized but also acknowledged and incorporated into the clinical decision-making process.
Open AccessMeasurement Uncertainty in Clinical Validation Studies of Sensors
Accurate clinical sensors and devices are essential to support optimal medical decision-making, and accuracy can be demonstrated through the conduct of clinical validation studies using validated reference sensors and/or devices for comparison. Typically unmeasurable, the true reference value can be substituted with an accepted physiological measurement with an associated uncertainty. We describe a basic model of measurement uncertainty that specifies the factors that may degrade the accuracy of an observed measurement value from a sensor, and we detail validation study design strategies that may be used to quantify and minimize these uncertainties. In addition, we describe a model that extends the observed measurement uncertainty to the resultant clinical decision and the factors that may impact the uncertainty of this decision. Clinical validation studies should be designed to estimate and minimize uncertainty that is unrelated to the sensor accuracy. The contribution of measurement observation uncertainty to clinical decision-making should be minimized but also acknowledged and incorporated into the clinical decision-making process.